Exhibit 99.1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS As at and for the three and nine months ended September 30, 2023 and 2022 (Unaudited - expressed in U.S. Dollars) XORTX THERAPEUTICS INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited - expressed in U.S. Dollars) | | | | December 31, | January 1, | | --- | --- | --- | --- | --- | | | | | 2022 | 2022 | | | | September 30, | Restated | Restated | | | Note | 2023 | (Note 2) | (Note 2) | | | | $ | $ | $ | | Assets | | ...

Election Results - Allen Davidoff received 3,432,152 votes (52.65%) for his election as director, while 3,087,324 votes (47.36%) were withheld[2] - William Farley was elected with 5,679,271 votes (87.11%), and 840,205 votes (12.89%) were withheld[2] Auditor Appointment - Smythe LLP was appointed as the auditor with 7,359,275 votes (99.78%) in favor, and 16,117 votes (0.22%) were withheld[3] Stock Option Plan - The stock option plan was re-approved with 6,048,425 votes (94.33%) in favor, while 363,453 votes (5.67%) were against[4]

Financial Performance - Net loss for the period was $1,832,035 for Q1 2023, compared to a net loss of $2,703,693 in Q1 2022, indicating an improvement of about 32%[3] - Basic and diluted loss per common share improved to $(0.11) in Q1 2023 from $(0.21) in Q1 2022[3] - The net loss for the three months ended March 31, 2023, was $2,703,693, compared to a net loss of $3,423,262 for the same period in 2022, indicating a reduction of approximately 21%[22] - The Company incurred a loss before other items of $2,875,983 for the three months ended March 31, 2022, compared to a loss of $3,641,406 in the same period of 2023[22] Cash and Assets - Cash and cash equivalents decreased to $7,908,461 as of March 31, 2023, down from $10,434,196 at the end of 2022, representing a decline of approximately 24%[2] - Total assets decreased to $9,658,813 as of March 31, 2023, down from $12,374,026 at the end of 2022, reflecting a reduction of about 22%[2] - The Company reported total current assets of $10,895,568 and total assets of $12,374,026 as of December 31, 2022, reflecting a decrease from $14,750,412 and $16,752,929 respectively[21] Liabilities and Equity - Total liabilities decreased significantly to $599,788 as of March 31, 2023, compared to $5,377,215 at the end of 2022, a reduction of approximately 89%[2] - Shareholders' equity increased to $9,059,025 as of March 31, 2023, up from $6,996,811 at the end of 2022, representing an increase of about 30%[2] - The Company’s total liabilities were reported at $5,377,215 as of December 31, 2022, compared to $7,286,499 previously reported[21] Research and Development - Research and development expenses were $1,046,957 in Q1 2023, a decrease of approximately 46% from $1,927,681 in Q1 2022[3] - The Company has not capitalized any development costs as of March 31, 2023, despite ongoing product development efforts[30] - The company plans to continue raising necessary capital to support its research and development activities and clinical studies[10] - XORTX Therapeutics is focused on developing therapies for progressive kidney disease, with ongoing efforts to secure funding for future projects[9] Shareholder Information - The weighted average number of common shares outstanding increased to 17,365,009 in Q1 2023, up from 12,989,687 in Q1 2022, reflecting an increase of approximately 34%[3] - The Company issued 2,959,000 common shares for the exercise of Pre-Funded Warrants at $0.0001 per share, raising $296 during the three months ended March 31, 2023[46] - The Company has a total of 17,989,687 common shares issued as of March 31, 2023, an increase from 15,030,687 at December 31, 2022[45] Obligations and Payments - The Company has an obligation to pay UFRF an annual license fee of $1,000 and milestone payments of $500,000 upon FDA approval for marketing in the U.S.[41] - The Company is obligated to pay royalties of up to 1.5% of net sales of products covered by the license until the expiration of patent claims or 10 years from the first commercial sale[41] - The company has committed to payments totaling $1,514,514 for clinical trials and other business activities expected to occur over the next two years, down from $1,994,232 as of December 31, 2022[79] Other Financial Metrics - The Company recognized a share-based payment expense of $39,550 during the three months ended March 31, 2023, compared to $68,078 in the same period of 2022[61] - The Company incurred issuance costs of $1,067,153 in connection with a public offering that closed on October 7, 2022[49] - The Company has a total of 10,127,076 warrants outstanding as of March 31, 2023, with a weighted average exercise price of $2.47[51] - The total present value of minimum lease payments related to the office lease obligation was $61,536 as of March 31, 2023[44] Currency and Reporting Changes - The Company changed its functional and presentation currency from CAD to USD effective January 1, 2023, to better reflect its business activities in the U.S.[17] Related Party Transactions - The company incurred related party transactions totaling $125,229 for wages and benefits for key executives during the three months ended March 31, 2023, compared to $155,399 in the same period of 2022[69] - Research and development fees paid to related parties amounted to $52,979 for the three months ended March 31, 2023, compared to $56,250 in 2022[74] Management and Executive Compensation - The company’s management services for officers amounted to $472,800 as of March 31, 2023, compared to $441,754 as of December 31, 2022[77]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Exhibit 99.3 XORTX THERAPEUTICS INC. ANNUAL INFORMATION FORM FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 MARCH 31, 2023 Unless otherwise stated, the information set forth in this AIF is as of December 31, 2022. i XORTX THERAPEUTICS INC. ANNUAL INFORMATION FORM FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 MARCH 31, 2023 REFERENCE INFORMATION TABLE OF CONTENTS In this annual information form (the "AIF"), a reference to the "Company", "XORTX", "we", "us", "our" and similar words refer to XORTX Therapeutics Inc. ...

Exhibit 99.1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended September 30, 2022 and 2021 (Unaudited - expressed in Canadian Dollars) XORTX THERAPEUTICS INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited - expressed in Canadian Dollars) | | | September 30, | December 31, | | --- | --- | --- | --- | | | Note | 2022 $ | 2021 $ | | Assets | | | | | Current | | | | | Cash and cash equivalents | 5 | 12,160,047 | 18,851,244 | | Accounts receivabl ...

Exhibit 99.1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and six months ended June 30, 2022 and 2021 (Unaudited - expressed in Canadian Dollars) XORTX THERAPEUTICS INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited - expressed in Canadian Dollars) | | | | December | | --- | --- | --- | --- | | | | June 30, | 31, | | | Note | 2022 $ | 2021 $ | | Assets | | | | | Current | | | | | Cash and cash equivalents | 5 | 13,420,636 | 18,851,244 | | Accounts receivable ...

Exhibit 99.1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (Unaudited - expressed in Canadian Dollars) 1 NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the condensed interim consolidated financial statements they must be accompanied by a notice indicating that the financial statements have not been reviewed b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...